Yakup Ergün @dr_yakupergun Twitter profile

Pinned Tweet

Yakup Ergün

7 months

My comment on Common Sense Oncology: We are all responsible ✨️Physicians should stand in the light of unbiased science, not under the influence of the pharmaceutical industry, to advocate for patients' rights. @TheLancetOncol

4

24

97

Last Seen Profiles

@Naughtycoup_xx

@DiaryGlacier

@gomaame50

@Satterthwaite_D

@sissymichi1975

@FrankRe91446579

@BlueDevil_HC

@DevOliRBX

@_NotAya

@mouthfulofnails

@repositoryink

@Afrinvest

@thsbcaStar

@rattibha

@govochto

@kakinoyu303

@feulleton

@equalityfl

@UNISONOurNHS

@mashumaro175449

@EndymionYT

@TheGoAheadGroup

@CarlsbadPolice

@stw_pdg

@PhilippineStar

@UWFSoftball

@dgn_893x

@walis_hcs

@mereohirosuke

@krisonly_

@cinnamoryeol

@mustafa51831905

@kanazawa_itaya

@RateGain

@iulianamihai

@cheseysgley

Yakup Ergün

@dr_yakupergun

10 months

@historyinmemes A tragic story highlighting the importance of understanding complex medical conditions. It's relieving to know that justice prevailed in the end. A lesson to be learned from this incident.

5

15

565

Yakup Ergün

@dr_yakupergun

1 year

@ovgunaercan Sayın hocam ben bir hekim olarak branşım olmadığı için acil tıbbi müdahale konusunda yorum yapmaktan imtina ediyorum, belki yanlış bilgi veririm diye. İyi niyetinizden şüphem yok ama tıbbi durumlar ile bilgilendirmeleri ilgili branşın hekimlerine bırakırsak daha uygun olacaktır.

1

2

350

Yakup Ergün

@dr_yakupergun

11 months

#ASCO23 D-TORCH: Topical diclofenac in prevention of hand-foot syndrome in pts receiving capecitabine 💥Topical diclofenac is effective in preventing all grades of HFS in patients receiving capecitabine New standard of care to prevent capecitabine associated HFS? @OncoAlert

11

145

301

Yakup Ergün

@dr_yakupergun

10 months

Breast cancer

2

94

295

Yakup Ergün

@dr_yakupergun

2 years

Adjuvant chemotherapy recommendations for stage II colon cancer: Joint chart of @ASCO and @myESMO guidelines @TotalHealthConf @oncotwitts @OncoAlert

7

106

273

Yakup Ergün

@dr_yakupergun

9 months

@historyinmemes The vaccine is the most important health discovery in human history. Trust science..

10

6

255

Yakup Ergün

@dr_yakupergun

10 months

@historyinmemes Discovering the essence of civilization through a healed bone is a testament to remarkable insight and profound wisdom.

1

6

236

Yakup Ergün

@dr_yakupergun

1 month

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases : SENOMAC trial "In clinically node-negative patients with sentinel lymph node biopsy showing macrometastasis (1 or 2), comprehensive ALND can be omitted" @OncoAlert

5

81

187

Yakup Ergün

@dr_yakupergun

1 year

From the ESMO "cancer of unknown primary" management guideline; Recommended IHC markers for differential diagnosis👇

1

69

180

Yakup Ergün

@dr_yakupergun

4 months

Breast cancer highlights from 2023: Knowledge to guide practice and future research 📌PubMed has 15,000 publications on BC in 2023. The authors have summarized the most important studies A great review👇 #bcsm

2

66

176

Yakup Ergün

@dr_yakupergun

9 months

@historyinmemes We don't know the owner, but because of this tombstone, Myia is immortal.

0

1

171

Yakup Ergün

@dr_yakupergun

1 year

@DrSarperSaglam Bu kitabı elime aldığım günden beri ders çalışıyorum. Acaba bitirmesek daha mı iyi olacaktı🤔

3

0

167

Yakup Ergün

@dr_yakupergun

1 year

Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors @JCO_ASCO 🔹Phase 2, 35 pts (27 CRC) ORR➡️82% ☑️pCR 65% (17 pts underwent surgery) 💥Tissue-agnostic therapy become the new standard for the neoadjuvant setting? @OncoAlert

0

75

158

Yakup Ergün

@dr_yakupergun

1 year

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative eBC: Evidence and Controversies 📌Increasing adjuvant treatment options in HER2-neg eBC are causing confusion. 💥This topic is discussed in this excellent review👇 @OncJournal @OncoAlert

2

65

154

Yakup Ergün

@dr_yakupergun

8 months

Platinum‐based chemotherapy for early triple‐negative breast cancer (Cochrane Database) 20 studies, 4.688 patients DFS and OS (Carbo)⬆️ Neoadj➡️HR: 0.63 and 0.69 Adj➡️HR 0.69 and 0.70 📌 Regardless of BRCA, HRD, LN positivity and anthracycline

2

74

154

Yakup Ergün

@dr_yakupergun

1 year

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline @ASCO @JCO_ASCO @OncoAlert

1

59

150

Yakup Ergün

@dr_yakupergun

1 year

Comparison of HER2-Zero and HER2-Low in terms of clinicopathological factors and survival in early-stage breast cancer: A Systematic Review and Meta-analysis Our meta-analysis is out now👇 1/3 @OncoAlert @OncBrothers @curijoey @stolaney1 @PTarantinoMD

4

46

150

Yakup Ergün

@dr_yakupergun

5 months

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up @myESMO @Annals_Oncology

0

59

148

Yakup Ergün

@dr_yakupergun

4 months

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline 🔹️ BRCA1/2 testing recommended for newly diagnosed breast cancer patients aged ≤65 and select cases >65 🔹️ Recurrent breast cancer patients eligible for PARP inhibitor therapy…

2

65

138

Yakup Ergün

@dr_yakupergun

11 months

ASCO Educational Book Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between @ASCO @OncoAlert

1

59

137

Yakup Ergün

@dr_yakupergun

2 months

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update

0

53

139

Yakup Ergün

@dr_yakupergun

9 months

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy 👇

0

56

138

Yakup Ergün

@dr_yakupergun

5 months

Systemic Therapy for Melanoma: ASCO Guideline Update Q and A .

2

57

137

Yakup Ergün

@dr_yakupergun

11 months

Treatment algorithms in mBC👇 From the #ASCO23 and #ESMOBreast23 presentations HR+/HER2- by Dr. @StoverLab HER2+ by Dr. Shanu Modi @OncoAlert

1

63

131

Yakup Ergün

@dr_yakupergun

1 year

Updated treatment recommendations for prostate cancer (ESMO) 💥Updated guideline with current results of treatment options such as triple combinations, PARP inhibitors, Lu-177👇 @myESMO @Annals_Oncology @OncoAlert

0

57

135

Yakup Ergün

@dr_yakupergun

8 months

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up @myESMO @Annals_Oncology @OncoAlert

0

62

134

Yakup Ergün

@dr_yakupergun

1 year

Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients? 🔍Five RCTs, 1.985 pts 💥No benefit in adding adjuvant oxaliplatin (HR:1.02) @JCO_ASCO @OncoAlert

2

45

132

Yakup Ergün

@dr_yakupergun

4 months

NORPACT-1 trial: Neoadjuvant FOLFIRINOX versus upfront surgery for resectable PDAC FOLFIRINOX vs Surgery mOS➡️25.1 vs 38.5 mo 💥This trial did not show a survival benefit from neoadjuvant FOLFIRINOX in resectable PDAC compared with upfront surgery

4

43

129

Yakup Ergün

@dr_yakupergun

6 months

Lifetime Cancer Risks in ''Hereditary Breast and Ovarian Cancer'' associated pathogenic variants👇 From @myESMO guide

0

59

127

Yakup Ergün

@dr_yakupergun

2 months

@ASCO NSCLC Guideline updates👇 Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline, Version 2023.3 Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline, Version 2023.3

1

63

124

Yakup Ergün

@dr_yakupergun

2 months

Management of infusion-related reactions in cancer therapy: strategies and challenges

0

86

121

Yakup Ergün

@dr_yakupergun

10 months

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management ✨️All about TKI toxicities An excellent review that should be on the reading list👇

0

42

122

Yakup Ergün

@dr_yakupergun

2 months

Vaccination of Adults With Cancer: ASCO Guideline

0

81

120

Yakup Ergün

@dr_yakupergun

2 months

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer 💥PFS and OS X2️⃣

0

48

121

Yakup Ergün

@dr_yakupergun

1 year

In HER2+ BC, the decision for PMRT should be made according to the node status at the time of diagnosis or according to the pathological stage after neoadjuvant therapy? 312 pts N+➡️55% ypN0 5y LRRFS👇 PMRT vs No-PMRT ypNO➡️97 vs 97% ypN1➡️85 vs 89% ypN2-3➡️92 vs 75%❗️…

0

60

119

Yakup Ergün

@dr_yakupergun

1 year

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival 💫Great article about an argument that will never end. @JCO_ASCO

0

59

120

Yakup Ergün

@dr_yakupergun

1 year

MMR and MSI Testing for ICI Therapy: ASCO Endorsement of College of American @Pathologists Guideline 🔹CRC➡️IHC and/or PCR or NGS 🔹GE and SB➡️IHC and/or PCR 🔹Endometrium➡️IHC 🔸TMB should not be used as a surrogate for dMMR @ASCO @JCO_ASCO @OncoAlert

0

47

118

Yakup Ergün

@dr_yakupergun

10 months

Safety profile T-DM1 with concurrent radiation therapy: a meta-analysis Brain RT + T-DM1 ❗️Radionecrosis➡️17% Adjuvan RT + T-DM1 ✅️Pneumonitis➡️<1% ✅️Skin toxicity➡️1% 📌Adjuvant RT concurrent T-DM1 appears safe @RadiotherapyOn1 @OncoAlert

0

59

116

Yakup Ergün

@dr_yakupergun

9 months

@historyinmemes Displaying cultural superiority is intolerant and unsettling. Leave these people alone...

2

1

110

Yakup Ergün

@dr_yakupergun

2 months

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial | Journal of Clinical Oncology Simple solutions to seemingly complex problems👇 @JCO_ASCO #ASCO23

4

53

112

Yakup Ergün

@dr_yakupergun

8 months

Excited to share our meta-analysis 💥According to the pooled analysis of the PENELOPE-B, PALLAS, MonarchE and NATALEE trials, there is a significant DFS benefit of CDK 4/6 inhibition, especially in stage 3 patients (HR: 0.67)

3

53

112

Yakup Ergün

@dr_yakupergun

1 year

💥HER2-expression in HER2-negative tumors follows a dynamic process 💥In this study, changes in HER2 status were observed in 37.3% of relapses 💥The incidence of HER2-Low is higher in advanced tumors (45%➡️50%) 💥Conversion from HER2-Zero to HER2-Low was observed more in the…

1

37

110

Yakup Ergün

@dr_yakupergun

2 months

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma A great review for weekend reading👇

0

30

110

Yakup Ergün

@dr_yakupergun

25 days

The antibody–drug conjugate landscape 💥A great mini-review of ADC development, showcasing advancements in targets, drugs, antibodies, linkers, and conjugation methods👇

0

30

111

Yakup Ergün

@dr_yakupergun

4 months

2023 MASCC and ESMO guideline update for the prevention of chemotherapy and radiotherapy induced nausea and vomiting @myESMO @ESMO_Open

0

64

106

Yakup Ergün

@dr_yakupergun

1 month

Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights @JCOOP_ASCO @OncoAlert

1

48

108

Yakup Ergün

@dr_yakupergun

1 year

According to our last meta-analysis in which we examined the effect of HER2-Low status on pCR and survival in eTNBC; 🔍12 studies, 4.094 patients pCR➡️similar (40% vs 38%) DFS and OS➡️better on HER2-Low @CBCjournal @OncoAlert

2

29

105

Yakup Ergün

@dr_yakupergun

1 year

Cancer statistics, 2️⃣0️⃣2️⃣3️⃣ ⬇️Cancer death rates continue to decline ⬆️The incidence of breast, prostate and endometrial cancer is increasing @CAonline @oncoalert

0

41

105

Yakup Ergün

@dr_yakupergun

10 months

Consensus molecular subtype in CRC👇

0

38

106

Yakup Ergün

@dr_yakupergun

1 year

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated ADAURA Trial @JCO_ASCO 4y DFS Stage 2-3A➡️70% vs 29% (HR:0.23) Stage 1B-3A➡️73% vs 38% (HR:0.27) CNS recurrence s2-3A➡️8% vs 14% s1B-3A➡️6% vs 11% G>3 AE 23% vs 14% @OncoAlert

1

35

105

Yakup Ergün

@dr_yakupergun

5 months

PAPILLON: Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

0

46

104

Yakup Ergün

@dr_yakupergun

1 month

Neoadjuvant Chemotherapy vs Upfront Surgery for Locally Advanced Colon Cancer: OPTICAL Trial 🔍744 pts, T3(*) or T4, 1:1 pCR➡️7% Progression➡️4 pts localy, 1 pts metastasis DFS, while favoring NAC, is not statistically significant @OncoAlert

2

38

105

Yakup Ergün

@dr_yakupergun

4 months

BRAF — a tumour-agnostic drug target with lineage-specific dependencies 💥An excellent review👇

0

38

101

Yakup Ergün

@dr_yakupergun

1 year

Immediate hypersensitivity reactions to antineoplastic agents: A practical guide for the oncologist 💥A great clinical guide 📌The most important message for us oncologists: When you suspect anaphylaxis, immediately administer 0.5 mg epinephrine IM❗️ @OncoAlert …

1

33

104

Yakup Ergün

@dr_yakupergun

4 months

Analysis of Breast Cancer Mortality in the US—1975 to 2019 💥Improvements in treatment and screening have led to a 58% reduction in breast cancer mortality 💥Of this reduction, 25% was attributed to mammography screening, 47% to stage 1-3 treatment and 29% to metastatic…

4

31

104

Yakup Ergün

@dr_yakupergun

1 year

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update @ASCO @JCO_ASCO @OncoAlert

2

30

99

Yakup Ergün

@dr_yakupergun

7 months

#ESMO23 ALINA trial: Adjuvant Alectinib vs Chemotherapy 3y DFS Stage 1B➡️92.3 vs 71.6% (HR:0.21) Stage 2➡️95.6 vs 66.3% (HR:0.24) Stage 3➡️92.7 vs 60.7% (HR:0.25) Practice-changing study💥💥 Presented by Dr. Ben Solomon @myESMO

7

54

102

Yakup Ergün

@dr_yakupergun

1 year

#ESMOBreast23 ''New algorithm for HER2 positive mBC'' Algorithm from presentation by Dr. Shanu Modi 👇 @OncoAlert @myESMO

1

37

100

Yakup Ergün

@dr_yakupergun

2 months

More is not always better! Many important drugs (expensive) in oncology have been approved for excessive doses...

2

36

100

Yakup Ergün

@dr_yakupergun

2 months

Biliary Tract Cancers: French National Clinical Practice Guidelines for diagnosis, treatments and follow-up A very comprehensive and great guide👇

1

40

99

Yakup Ergün

@dr_yakupergun

9 months

@historyinmemes Hypatia

2

1

97

Yakup Ergün

@dr_yakupergun

1 month

Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer An excellent review👇

1

37

99

Yakup Ergün

@dr_yakupergun

22 days

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin: METALLICA 🔍Normoglycemic pts (Cohort A) and prediabetic pts (B) G3-4 HG (first 8 weeks) Cohort A➡️2.1% Cohort B➡️15% Prophylactic metformin✅️ @OncoAlert …

4

42

98

Yakup Ergün

@dr_yakupergun

1 month

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer : ALINA Trial @OncoAlert

2

46

99

Yakup Ergün

@dr_yakupergun

1 year

Olaparib plus Beva first-line maintenance in ovarian cancer: final OS results from the PAOLA-1/ENGOT-ov25 trial mOS for ITT➡️56.5 vs 51.6 mos, HR:0.92❗️ mOS for HRD+➡️75.2 vs 57.3 m, HR: 0.62✅ mPFS for HRD+➡️46.8 vS17.6 m, HR: 0.41✅ @OncoAlert @Annals_Oncology …

0

31

97

Yakup Ergün

@dr_yakupergun

7 months

#ESMO23 DESTINY-PanTumor01: Efficacy and safety of T-DXd in pts with solid tumors harboring specific HER2m+ mF/U: 8.6 mo ORR All➡️29.4% Endometrial➡️100% (n:2) Cervical➡️66.7 (n:3) Breast➡️50% (n:20) CRC➡️20% (n:20) Panc➡️0% (n:5) ILD➡️(10.8% [G3, n=1; G5, n=2]) @OncoAlert

2

42

98

Yakup Ergün

@dr_yakupergun

1 year

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study @JCO_ASCO Pembro + ChT vs ChT 5y OS➡️18.4 vs 9.7% (HR:0.71) 5y PFS➡️10.8 vs 3.5% (HR:0.62) ORR➡️62% vs 39% @OncoAlert

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase...

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...

ascopubs.org

0

38

96

Yakup Ergün

@dr_yakupergun

3 months

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

0

36

98

Yakup Ergün

@dr_yakupergun

9 months

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up👇 @myESMO @Annals_Oncology @OncoAlert

2

37

98

Yakup Ergün

@dr_yakupergun

7 months

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline 💥Systemic treatment recommendations for well diff G1-2-3 GEPNETs👇 @ASCO @JCO_ASCO @OncoAlert

1

50

97

Yakup Ergün

@dr_yakupergun

1 year

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update ⚡️Update on the integration of triple therapies into prostate cancer treatment👇 @ASCO @JCO_ASCO @OncoAlert

0

46

97

Yakup Ergün

@dr_yakupergun

2 months

Ribociclib plus Endocrine Therapy in Early Breast Cancer : NATALEE 3y-iDFS: 90.4% vs 87.1% (HR:0.75)

3

26

96

Yakup Ergün

@dr_yakupergun

7 months

#ESMO23 Evolution of oncology🙂

4

19

93

Yakup Ergün

@dr_yakupergun

1 year

Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? An excellent review👇

3

25

94

Yakup Ergün

@dr_yakupergun

3 months

The CREATE-X study's first efficacy analysis was presented at the 2015 SABCS. In June 2017, the final results were published in NEJM. Adjuvant capecitabine was recommended in ASCO guidelines starting May 2018. The KN-522 trial initiated patient enrollment in March 2017,…

Paolo Tarantino

@PTarantinoMD

3 months

KEYNOTE-522 outcomes by RCB out on @Annals_Oncology . Largest benefit from pembro was observed in the RCB-2 group. Striking difference in 3-year EFS between RCB-1 (≃84%) and RCB-3 (≃30%): not all residual disease is created equal!

1

69

162

6

17

94

Yakup Ergün

@dr_yakupergun

8 months

Checkpoint inhibitors and anti-angiogenic agents: a winning combination Weekend reading👇

1

39

93

Yakup Ergün

@dr_yakupergun

11 months

#ASCO23 Treatment algorithm for HR+/HER2- mBC From the excellent presentation by Dr. @StoverLab @OncoAlert

0

36

93

Yakup Ergün

@dr_yakupergun

1 year

PRIMARY THERAPY OF EARLY BREAST CANCER Evidence, Controversies, Consensus 18th St.Gallen International Breast Cancer Conference @stolaney1 @curijoey @hoperugo @PTarantinoMD @OncoAlert @OncBrothers @prat_aleix

0

39

93

Yakup Ergün

@dr_yakupergun

4 months

Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer "Most ER-low+/HER2− breast cancers are basal-like (>80%), with Risk Score≥26 suggesting these tumors are similar to triple-negative disease"

3

37

93

Yakup Ergün

@dr_yakupergun

11 months

#ASCO23 The importance of circadian rhythm A very interesting study.. 💥According to this study, evening tamoxifen intake is associated with an improved DFS in high-risk HR+/HER2- breast cancer patients The work of Dr. Sylvie Giacchetti and colleagues👇 @OncoAlert

3

36

91

Yakup Ergün

@dr_yakupergun

3 months

The treatment of Advanced Melanoma: Current approaches and new challenges 🔹️A great review on melanoma with rapidly expanding treatment options👇

2

29

90

Yakup Ergün

@dr_yakupergun

2 years

Median 6.6 years follow-up results of the MONALEESA-2 trial; ribociclib plus letrozole vs. letrozole in mBC first-line ☑️Median OS; 63.9 vs. 51.4 months, HR: 0.76 ☑️72 months OS rate; 44% vs. 32% ☑️ No new safety signals @NEJM @OncoAlert @TotalHealthConf 10.1056/NEJMoa2114663

0

40

89

Yakup Ergün

@dr_yakupergun

3 months

Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions - Cancer Treatment Reviews

1

39

90

Yakup Ergün

@dr_yakupergun

1 year

Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line ChT in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC) FOLFIRI + Beva vs FOLFIRI 6-month OS➡️53% vs 60% Beva🚫 FOLFIRI may be a second-line option @OncoAlert

2

25

89

Yakup Ergün

@dr_yakupergun

10 months

@historyinmemes In every story about Thomas Edison, those close to him lose, but he always wins. interesting

2

1

86

Yakup Ergün

@dr_yakupergun

9 months

Novel targets for immune checkpoint inhibition in cancer A great review for weekend reading👇

1

27

90

Yakup Ergün

@dr_yakupergun

4 months

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline Suggestions for alternative treatment approaches in cases of access problems👇 (In the hope that all patients have fair access to effective treatments)

4

34

89

Yakup Ergün

@dr_yakupergun

1 year

Role of Immunotherapy in Breast Cancer @JCOOP_ASCO 💥A good review on the role of immunotherapy in early and advanced breast cancer. @SayaJacob3 @laura_huppert @hoperugo

0

36

89

Yakup Ergün

@dr_yakupergun

10 months

Management of Stage III NSCLC: ASCO Guideline Rapid Recommendation Update Resectable stage 3➡️neoadjuvant therapy should be standard EGFR mt(19, 21)➡️Osimertinib after platinum-based ChT @JCO_ASCO @ASCO @OncoAlert

0

34

89

Yakup Ergün

@dr_yakupergun

8 months

Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Randomized Phase II Trial 🔍78 patients with 122 high-risk bone metastases RT👉SRE⬇️ Hospitalization⬇️ OS⬆️

0

37

87

Yakup Ergün

@dr_yakupergun

2 years

Treatment of mCRC: ASCO Guideline 🔹Anti-EGFR with triplet ChT is not recommended 🔹CRS may be recommended for selected pts with PM 🔸HIPEC is not recommended 🔹SBRT may be recommended for pts with oligometastases of the liver... @JCO_ASCO @OncoAlert

2

45

86

Yakup Ergün

@dr_yakupergun

13 days

A great review about the present and future of tumor-agnostic treatments👇 @OncoAlert

0

42

88

Yakup Ergün

@dr_yakupergun

4 months

Adjuvant Chemotherapy for Older Adult Patients With Biliary Tract Cancer 🔍Retrospective, 8091 older adult pts (>70y) 💥Adjuvant chemotherapy did not improve survival❗️ 📌This patient group needs to be further included in clinical trials @JAMANetworkOpen …

1

35

86

Yakup Ergün

@dr_yakupergun

5 months

Dacomitinib in EGFR-mutant NSCLC with brain metastasis Treatment naive 30 pts iORR➡️96.7% (CR:63.3%) mPFS➡️17.5 mo (intra/extracranial) 💥Highly impressive efficacy in cranial metastatic patients without severe symptomatic brain metastases, such as the need for RT or…

1

33

87

Yakup Ergün

@dr_yakupergun

6 months

FLAURA 2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

0

24

86

Yakup Ergün

@dr_yakupergun

7 months

The CDK4/6 Inhibitors Biomarker Landscape: the most Relevant Biomarkers of Response or Resistance for Further Research and Potential Clinical Utility 💥Excellent review for weekend reading👇

3

22

87

Yakup Ergün

@dr_yakupergun

1 year

How I treat endocrine-dependent metastatic breast cancer A great review👇 @ESMO_Open @OncoAlert @OncologyAdvance

0

26

85

Yakup Ergün

@dr_yakupergun

8 months

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer 💥An excellent review👇

2

34

84

Yakup Ergün

@dr_yakupergun

4 months

Exploring the next generation of antibody–drug conjugates 📌Bispecific ADCs, probody–drug conjugates, immune-stimulating ADCs, protein-degrader ADCs and dual-drug ADCs.... The scope of ADCs is expanding. Great review on this topic👇

1

24

86